Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease

Published:2019-09-16 Issue:10 Volume:129 Page:4451-4463
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Fajgenbaum David C.^ORCID,Langan Ruth-Anne^ORCID,Japp Alberto Sada,Partridge Helen L.^ORCID,Pierson Sheila K.,Singh Amrit^ORCID,Arenas Daniel J.^ORCID,Ruth Jason R.,Nabel Christopher S.,Stone Katie,Okumura Mariko,Schwarer Anthony,Jose Fábio Freire,Hamerschlak Nelson^ORCID,Wertheim Gerald B.,Jordan Michael B.,Cohen Adam D.^ORCID,Krymskaya Vera,Rubenstein Arthur,Betts Michael R.,Kambayashi Taku,van Rhee Frits,Uldrick Thomas S.^ORCID

Funder

Castleman’s Awareness & Research Effort

Penn Center for Precision Medicine

University of Pennsylvania

National Heart, Lung, and Blood Institute

National Institutes of Health

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/126091/files/pdf

Reference44 articles.

1. Use of a claims database to characterize and estimate the incidence rate for Castleman disease

2. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease;Soulier;Blood,1995

3. Idiopathic multicentric Castleman's disease: a systematic literature review

4. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

5. Castleman-Kojima Disease (TAFRO Syndrome) : A Novel Systemic Inflammatory Disease Characterized by a Constellation of Symptoms, Namely, Thrombocytopenia, Ascites (Anasarca), Microcytic Anemia, Myelofibrosis, Renal Dysfunction, and Organomegaly : A Status Report and Summary of Fukushima (6 June, 2012) and Nagoya Meetings (22 September, 2012)

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO;Biomedicines;2024-06-14

2. TAFRO Syndrome and COVID-19;Biomedicines;2024-06-11

3. Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report;British Journal of Haematology;2024-06-10

4. Remodeling of T-cell mitochondrial metabolism to treat autoimmune diseases;Autoimmunity Reviews;2024-06

5. Idiopathic multicentric Castleman disease - TAFRO results in high levels of mTOR activator SVEP1, tissue factor, and endotheliopathy;Blood Vessels, Thrombosis & Hemostasis;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3